InvestLog
← Back to Research← 返回研究
VRTXEarnings ReleaseSource checkedAugust 3, 2026by InvestLog AI

VRTX earnings release — EPS in line -0.2% · revenue beat +3.1%福泰制药 (VRTX) 财报发布 — EPS 基本符合预期-0.2% · 营收 高于预期+3.1%

Key Results

Vertex Pharmaceuticals Incorporated (VRTX) published results at 2026-08-03 16:01:00.

Actual vs Consensus

  • EPS: $4.73 vs $4.74 estimate, in line-0.2%.
  • Revenue: $3.3B vs $3.2B estimate, beat+3.1%.

    • Profitability and Cash Flow

  • Period: 2026 Q2 period ended 2026-06-30
  • Revenue: $3.3B; YoY: +12.5%; QoQ: +11.6%
  • Gross profit: $2.8B; Gross margin: 85.3%
  • Operating income: $1.2B; Operating margin: 37.4%; YoY: +8.3%; QoQ: +9.6%
  • Net income: $1.1B; GAAP diluted EPS: $4.31; YoY: +6.5%; QoQ: +6.6%
  • Cash: $0; Total debt: $2.0B; Net debt: $2.0B

    • Official release: Vertex Reports Second Quarter 2026 Financial Results

    核心结果

    福泰制药 (VRTX) 已发布财报，发布时间：2026-08-03 16:01:00。

    实际值与市场预期

  • EPS：$4.73 vs $4.74 预期，基本符合预期-0.2%。
  • 营收：$3.3B vs $3.2B 预期，高于预期+3.1%。

    • 财务指标

  • 期间：2026 Q2 period ended 2026-06-30
  • 营收：$3.3B；同比：+12.5%；环比：+11.6%
  • 毛利润：$2.8B；毛利率：85.3%
  • 经营利润：$1.2B；经营利润率：37.4%；同比：+8.3%；环比：+9.6%
  • 净利润：$1.1B；GAAP 稀释 EPS：$4.31；同比：+6.5%；环比：+6.6%
  • 现金：$0；总债务：$2.0B；净债务：$2.0B

    • 官方公告：Vertex Reports Second Quarter 2026 Financial Results

    View VRTX stock details ->查看 VRTX 个股详情 ->

    This earnings research was prepared from company results, regulatory filings, financial statements, and earnings-call transcripts or official replays. It is for informational purposes only and does not constitute investment advice.这篇财报研究基于公司业绩公告、监管文件、财务报表，以及财报电话会议记录或官方回放整理。内容仅供参考，不构成投资建议。